COVID-19 Treatment 'Remdesivir' Effective Against 11 Variants Including Delta in Cell Experiments (Update)

[Image source=Yonhap News]

[Asia Economy Reporter Seo So-jeong] The COVID-19 treatment drug 'Remdesivir' has been found to maintain antiviral efficacy against 11 types of variant viruses, including the Delta variant.

On the 6th, Kwon Jun-wook, the 2nd Deputy Director of the Central Disease Control Headquarters, stated at the regular COVID-19 briefing, "Through cell experiments, we analyzed the efficacy of Remdesivir against a total of 11 variants, including four major variants such as the Delta variant, five other variants, and two variants found domestically, and confirmed that the antiviral efficacy was maintained across all 11 variants."

The National Institute of Health conducted experiments using compounds with the same ingredients as Remdesivir, which is currently used for patient treatment.

The variant viruses used in the experiments included 11 types: major variants such as Alpha, Beta, Gamma, and Delta, as well as Kappa, Epsilon, Zeta, Eta, Iota (domestic G group), B.1.619, and B.1.620.

The experimental results confirmed that, compared to the original COVID-19 virus (GR), the antiviral efficacy was maintained against all 11 variant viruses regardless of genetic mutations in the virus.

Deputy Director Kwon said, "In the ongoing situation of variant virus spread, we plan to continuously conduct efficacy evaluations of antiviral drugs and other treatments."

This content was produced with the assistance of AI translation services.